Scotiabank raised the firm’s price target on Twist Bioscience (TWST) to $54 from $50 and keeps an Outperform rating on the shares. The company wrapped up FY24 on a strong note, beating consensus and guidance across the board, the analyst tells investors. Looking ahead, the firm expects the company to remain well-positioned to continue to outperform its peer group across multiple macro scenarios.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TWST:
- Twist Bioscience price target raised to $48 from $46 at Baird
- Twist Bioscience Reports Record Revenue in 2024
- Twist Bioscience price target lowered to $52 from $55 at Barclays
- Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz
- Morning Movers: Liberty Energy, Tesla up after President-elect Trump alliance
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
